4 years ago

The NeuroSAFE Approach to Nerve Sparing in Robotic Assisted Radical Prostatectomy in a British Setting – A Prospective Observational Comparative Study

Vinaya Srirangam, Bhavan Rai, George Mirmilstein, Samita Agarwal, Ashish Narula, Nikhil Vasdev, Olayinka Gbolahan, Jim Adshead, Tim Lane
Objectives To evaluate the NeuroSAFE technique in a British setting in men undergoing RALP. Patients and Methods We retrospectively analysed our prospectively maintained database of patients who underwent RALP between Nov 2008 and Feb 2017. We examined preoperative pathological and functional parameters, intra-operative nerve sparing, post-operative histology as well as functional and oncological follow-up. We compared those who had a NeuroSAFE approach and those who had nerve sparing without NeuroSAFE. We also compared all the RALPs before and after the introduction of NeuroSAFE. Statistical analysis was done using the two tailed T-test and Chi-Squared analysis. Results This single surgeon series included 417 RALPs including 120 NeuroSAFEs. The NeuroSAFE cohort had a greater proportion of D'Amico high risk disease (30.8% vs 9.6%, p<0.0001), higher Gleason scores and higher pT stage compared to the non-NeuroSAFE nerve spares. After the introduction of NeuroSAFE, more preoperatively potent men underwent bilateral nerve sparing with pT2 disease (84.6% vs. 66.3%, p=0.002) and more overall nerve spares were performed in patients with pT3 disease (65.1% vs 36.7%, p=0.012). Overall positive surgical margin rates (PSMR) were lower in the NeuroSAFE cohort compared to those who had nerve sparing without NeuroSAFE (9.2% vs 17.8%, p=0.04). The 12-months potency rates were also higher in the NeuroSAFE cohort for both bilateral (77.3% vs 50.9% p=0.009) and unilateral (70.6% vs 40%, p=0.04) nerve spares. Pad-free continence was also higher in the NeuroSAFE group (85.7% vs 70.9%, p=0.019), but there was no significant difference between those who were wearing 1 safety pad or less. Although we only had short term oncological follow-up, it did not significantly differ between the two groups. Conclusions Adoption of NeuroSAFE allowed us to offer nerve sparing in higher risk patients, whilst reducing PSMR and at the same time improving potency at 12 months. This article is protected by copyright. All rights reserved.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/bju.14078

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.